IPP Bureau
Senores Pharmaceuticals gets SEBI nod for IPO
By IPP Bureau - October 21, 2024
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test
By IPP Bureau - October 21, 2024
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
PM Modi inaugurates Rs. 110 crore R Jhunjhunwala Sankara Eye Hospital in Varanasi
By IPP Bureau - October 21, 2024
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24
By IPP Bureau - October 21, 2024
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules
By IPP Bureau - October 21, 2024
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Zydus receives final approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 mg
By IPP Bureau - October 19, 2024
Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad
Granules India receives ANDA approval for Bupropion Hydrochloride ER Tablets
By IPP Bureau - October 19, 2024
Granules now has a total of 67 ANDA approvals from the USFDA
Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study
By IPP Bureau - October 19, 2024
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years
By IPP Bureau - October 19, 2024
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Gland Pharma appoints Shyamakant Giri as CEO
By IPP Bureau - October 19, 2024
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
AstraZeneca advances science of infectious disease protection at IDWeek 2024
By IPP Bureau - October 18, 2024
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
FDA approves VYALEV for adults living with advanced parkinson's disease
By IPP Bureau - October 18, 2024
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
MedGenome completes 10 years in genomics in India
By IPP Bureau - October 18, 2024
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Lupin launches first generic of Pred Forte in US
By IPP Bureau - October 16, 2024
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Lupin launches Aptivate Achi Bhookh Fest in Mumbai and Suburbs
By IPP Bureau - October 16, 2024
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
